Skip to main content
Fig. 3 | Journal of Translational Medicine

Fig. 3

From: Combining serum inflammation indexes at baseline and post treatment could predict pathological efficacy to anti‑PD‑1 combined with neoadjuvant chemotherapy in esophageal squamous cell carcinoma

Fig. 3

The prediction ability of serum inflammation indexes to distinguish patients with pCR and non-pCR. A NLR at post treatment of first period; B NLR at baseline; C NLR at post treatment of second period; D NLR at post treatment of third period; E LMR at baseline; F LMR at post treatment of first period; G LMR at post treatment of second period; H LMR at post treatment of third period (I) PLR at baseline; J PLR at post treatment of first period; K PLR at post treatment of second period; L PLR at post treatment of third period; M SII at baseline; N SII at post treatment of first period; O SII at post treatment of second period; P SII at post treatment of third period

Back to article page